Antifungal activity of splenic, liver and pulmonary macrophages against Candida albicans and effects of macrophage colony-stimulating factor

Medical Mycology

Volumn 38, Issue 2, 2000, Pages 161-168

  Roilides, E ^a,b   Lyman, C A ^b   Sein, T ^b   Gonzalez, C ^b   Walsh, Thomas J ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Candida; M CSF; Tissue macrophages

Indexed keywords

COLONY STIMULATING FACTOR 1;

ADHERENT CELL; ANIMAL CELL; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; FEMALE; IN VITRO STUDY; KUPFFER CELL; LUNG ALVEOLUS MACROPHAGE; MACROPHAGE ACTIVATION; MACROPHAGE FUNCTION; NONHUMAN; PHAGOCYTOSIS; RABBIT;

ANIMALIA; CANDIDA; CANDIDA ALBICANS; ORYCTOLAGUS CUNICULUS;

EID: 0033998219     PISSN: 13693786     EISSN: None     Source Type: Journal    
DOI: 10.1080/mmy.38.2.161.168     Document Type: Article

References (41)

1. Wenzel RP. Nosocomial candidemia: risk factors and attributable mortality. Clin Infect Dis 1995; 20: 1531-1534.
2. Anaissie EJ, Rex JH, Uzun O, Vartivarian S. Predictors of adverse outcome in cancer patients with candidemia. Am J Med 1998; 104: 238-245.
3. Walsh TJ, Whitcomb PO, Revankar SG, Pizzo PA. Successful treatment of hepatosplenic candidiasis through repeated cycles of chemotherapy and neutropenia. Cancer 1995; 76: 2357-2362.
4. Schwocho LR, Moon RJ. Clearance and killing of Candida albicans in the perfused mouse liver. Mycopathologia 1981; 76: 175.
5. Redmond HP, Shou J, Gallagher HJ, Kelly CS, Daly JM. Macrophage-dependent candidacidal mechanisms in the murine system. Comparison of murine Kupffer cell and peritoneal macrophage candidacidal mechanisms. J Immunol 1993; 150: 3427-3433.
6. Leenen PJ, Radosevic K, Voerman JS, et al. Heterogeneity of mouse spleen dendritic cells: in vivo phagocytic activity, expression of macrophage markers, and subpopulation turnover. J Immunol 1998; 160: 2166-2173.
7. Vecchiarelli A, Todisco T, Puliti M, Dottorini M, Bistoni F. Modulation of anti-Candida activity of human alveolar macrophages by interferon-γ or interleukin-1α. Am J Resp Cell Mol Biol 1989; 1: 49-55.
8. Haron E, Vartivarian S, Anaissie E, Dekmezian R, Bodey GP. Primary Candida pneumonia. Experience at a large cancer center and review of the literature. Medicine (Baltimore) 1993; 72: 137-142.
9. Vazquez-Torres A, Balish E. Macrophages in resistance to candidiasis. Microbiol Mol Biol Rev 1997; 61: 170-192.
10. Nemunaitis J. Use of macrophage colony-stimulating factor in the treatment of fungal infections. Clin Infect Dis 1998; 26: 1279-1281.
11. Motoyoshi K. Biological activities and clinical application of M-CSF. Intern J Hematol 1998; 67: 109-122.
12. Khwaja A, Johnson B, Addison IE, et al. In vivo effects of macrophage colony-stimulating factor on human monocyte function. Br J Haematol 1991; 77: 25-31.
13. Wing EJ, Ampel NM, Waheed A, Shadduck RK. Macrophage colony-stimulating factor (M-CSF) enhances the capacity of murine macrophages to secrete oxygen reduction products. J Immumol 1985; 135: 2052-2056.
14. Roilides E, Sein T, Holmes A, et al. Effects of macrophage colony-stimulating factor on antifungal activity of mononuclear phagocytes against Aspergillus fumigatus. J Infect Dis 1995; 172: 1028-1034.
15. Roilides E, Lyman CA, Mertins SD, et al. Ex vivo effects of macrophage colony-stimulating factor on human monocyte activity against fungal and bacterial pathogens. Cytokine 1996; 8: 42-48.
16. Karbassi A, Becker JM, Foster JS, Moore RN. Enhanced killing of Candida albicans by murine macrophages treated with macrophage colony-stimulating factor: evidence for augmented expression of mannose receptors. J Immunol 1987; 139: 417-421.
17. Cenci E, Bartocci A, Puccetti P, et al. Macrophage colony-stimulating factor in murine candidiasis: serum and tissue levels during infection and protective effect of exogenous administration. Infect Immun 1991; 59: 868-872.
18. Khemani S, Brummer E, Stevens DA. In vivo and in vitro effects of macrophage colony-stimulating factor (M-CSF) on bronchoalveolar macrophages for antihistoplasmal activity. Int J Immunopharmac 1995; 17: 49-53.
19. Nassar F, Brummer E, Stevens DA. Effect of in vivo macrophage colony-stimulating factor on fungistasis of bronchoalveolar and peritoneal macrophages against Cryptococcus neoformans. Antimicrob Agents Chemother 1994; 38: 2162-2164.
20. Nemunaitis J, Meyers JD, Buckner D, et al. Phase I trial of recombinant human macrophage colony-stimulating factor in patients with invasive fungal infections. Blood 1991; 78: 907-913.
21. Nemunaitis J, Shannon-Dorcy K, Appelbaum FR, et al. Long-term follow-up of patients with invasive fungal disease who received adjunctive therapy with recombinant human macrophage colony-stimulating factor. Blood 1993; 82: 1422-1427.
22. Ohno R, Miyawaki S, Hatake K. et al. Human urinary macrophage colony-stimulating factor reduces the incidence and duration of febrile neutropenia and shortens the period required to finish three courses of intensive consolidation therapy in acute myeloid leukemia: a double-blind controlled study. J Clin Oncol 1997; 15: 2954-2965.
23. Walsh TJ, McEntee C, Dixon DM. Tissue homogenization with sterile reinforced polyethylene bags for quantitative culture of Candida albicans. J Clin Microbiol 1987; 25: 931-932.
24. Walsh TJ, Aoki S, Mechinaud F, et al. Effects of preventive, early, and late antifungal chemotherapy with fluconazole in different granulocytopenic models of experimental disseminated candidiasis. J Infect Dis 1990; 161: 755-760.
25. Roilides E, Holmes A, Blake C, Pizzo PA, Walsh TJ. Effects of granulocyte colony-stimulating factor and interferon-γ on antifungal activity of human polymorphonuclear neutrophils against pseudohyphae of different medically important Candida species. J Leukoc Biol 1995; 57: 651-656.
26. Levitz SM, Diamond RD. A rapid colorimetric assay of fungal viability with the tetrazolium salt MTT. J Infect Dis 1985; 152: 938-945.
27. Magee DM, Wing EJ, Ampel NM, Waheed A, Shadduck RK. Macrophage colony-stimulating factor enhances the expression of Fc receptors on murine peritoneal macrophages. Immunology 1987; 62: 373-378.
28. Cheers C, Hill M, Haigh AM, Stanley ER. Stimulation of macrophage phagocytic but not bactericidal activity by colony-stimulating factor 1. Infect Immun 1989; 57: 1512-1516.
29. Arai T, Mikami Y, Yokoyama K. Phagocytosis of Candida albicans by rabbit alveolar macrophages and guinea pig neutrophils. Subouraudia 1977; 15: 171-177.
30. Lehrer RI, Ferrari LG, Patterson J, Sorrell T. Fungicidal activity of rabbit alveolar and peritoneal macrophages against Candida albicans. Infect Immun 1980; 28: 1001.
31. Danley DL, Polakoff J. Rapid killing of monocytes in vitro by Candida albicans yeast cells. Infect Immun 1986; 51: 307-313.
32. Mufson RA, Aghajanian J, Wong G, Woodhouse C, Morgan AC. Macrophage colony-stimulating factor enhances monocyte and macrophage antibody dependent cell-mediated cytotoxicity. Cell Immunol 1989; 119: 182-192.
33. Munn DH, Cheung N-KV. Phagocytosis of tumor cells by human monocytes cultured in recombinant macrophage colony-stimulating factor. J Exp Med 1990; 172: 231-237.
34. Zamkoff KW, Hudson J, Groves ES, et al. A Phase I trial of recombinant human macrophage colony-stimulating factor by rapid intravenous infusion in patients with refractory malignancy. J Immunother 1992; 11: 103-110.
35. Albert RK, Embree LJ, McFeely JE, Hickstein DD. Expression and function of beta-2 integrins on alveolar macrophages from human and nonhuman primates. Am J Resp Cell Mol Biol 1992; 7: 182-189.
36. Kuhlman M, Joiner K, Ezekowitz RAB. The human mannose-binding protein functions as an opsonin. J Exp Med 1989; 169: 1733-1745.
37. Andoh A, Fujiyama Y, Kitoh K, et al. Macrophage colony-stimulating factor (M-CSF) enhances complement component C3 production by human monocytes/macrophages. Int J Hematol 1993; 57: 53-59.
38. Sakurai T, Suzu S, Yamada M, et al. Induction of tumor necrosis factor in mice by recombinant human macrophage colony-stimulating factor. Jpn J Cancer Res 1994; 85: 80-85.
39. Motoyosi K, Yosida K, Hatake K, et al. Recombinant and native human urinary colony-stimulating factor directly augments granulocyte-macrophage colony-stimulating factor production of human peripheral blood monocytes. Exp Hematol 1989; 17: 68-71.
40. Moore RN, Oppenheim JJ, Farrar JJ, et al. Production of lymphocyte-activating factor (interleukin 1) by macrophages activated with colony-stimulating factors. J Immunol 1980; 125: 1302-1305.
41. Baghian A, Lee KW. Role of activated macrophages in resistance to systemic candidosis. J Leukoc Biol 1988; 44: 166-171.